

## SUPPLEMENTARY MATERIAL

Table 1. **Baseline demographic and clinical data of the study population.** The following criteria were used to select asthmatic patients: (1) a clinical history of asthma; (2) either bronchodilator responsiveness (>12% and 200 ml improvement in FEV<sub>1</sub> after 180 µg salbutamol metered-dose inhaler) or positive response to a methacholine bronchoprovocation test. The level of asthma severity was established according to the pharmacological treatment used to control the disease.

	<b>C</b>	<b>A</b>	<b>OA</b>	<b>O</b>
<b>N,</b>	13	12	22	11
<b>Age, years</b>	43 (35 - 56)	54 (41 - 59)	57 (51 - 61)	48 (45 - 63)
<b>Female, n (%)</b>	11 (84.6)	10 (83.3)	18 (81.8)	9 (81.8)
<b>BMI, kg/m<sup>2</sup></b>	24.5 (22.5 - 26.1)	23.3 (22.5 - 26.2)	39.2 (36.1 - 46.5) *#	43.8 (38.9 - 47.5) *#
<b>Mild asthma, n (%)</b>	-	0 (0)	4 (18.2)	-
<b>Moderate asthma, n (%)</b>	-	5 (41.7)	5 (22.7)	-
<b>Severe asthma, n (%)</b>	-	7 (58.3)	13 (59.1)	-
<b>FVC, % pred</b>	101.0 (95.2 - 106.8)	121 (101.1 - 137.0) *	110.0 (89.0 - 117.5)	107.0 (78.0 - 124.5)
<b>FEV<sub>1</sub>, % pred</b>	100.5 (83.0 - 109.0)	78.0 (66.0 - 94.0) *	77.0 (61.0 - 92.5) *	87.0 (67.5 - 93.5) *
<b>FEV<sub>1</sub>/FVC</b>	78.0 (68.5 - 83.5)	62.0 (53.0 - 74.0) *	75.0 (64.0 - 79.5) #	75.0 (64.0 - 81.5) #
<b>FeNO</b>	31.0 (19.0 - 51.0)	40.0 (15.7 - 57.0)	35.5 (23.5 - 57.2)	32.0 (16.0 - 45.0)
<b>ICS<sup>§</sup>, n (%)</b>	-	10 (83.3)	16 (72.7)	-
<b>IgE, kU/L</b>	41.4 (22.1 - 75.6)	82.2 (38.7 - 382.0)	63.8 (19.4 - 131.8)	48.3 (19.2 - 110.0)
<b>Eosinophils, %</b>	3.0 (1.9 - 4.1)	5.6 (3.7 - 9.5) *	3.5 (2.4 - 6.2)	3.0 (1.5 - 16.6)
<b>Eosinophils, cells/mm<sup>3</sup></b>	200 (100 - 300)	300 (200 - 600)	200 (200 - 500)	200 (100 - 300)
<b>25(OH)D, ng/ml</b>	25.5 (19.3 - 41.7)	23.0 (18.7 - 27.7)	26.0 (18.3 - 44.8)	25.9 (11.3 - 45.0)

Data presented as medians (25<sup>th</sup> - 75<sup>th</sup> percentile). BMI, body mass index; C, non-obese non-asthmatics; FeNO, fractional exhaled nitric oxide; FEV<sub>1</sub>, forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroids; IgE, immunoglobulin E; NOA, non-obese asthmatics; O, obese subjects; OA, obese asthmatics; pred, predicted. \*  $p < 0.05$ , compared with C; #  $p < 0.05$ , compared with NOA; Mann-Whitney U test. § For NOA and OA patients who received ICS, the mean  $\pm$  SD of the ICS dose in budesonide equivalents was 557.1  $\pm$  256.6 and 1222.1  $\pm$  862.9 µg/day, respectively.